HYTN Innovations Inc (TSE:HYTN) has released an update.
HYTN Innovations Inc. has completed its acquisition of Prism Scientific Labs, aiming to enhance its psychedelic compound manufacturing capabilities, particularly in the field of psilocybin. The deal secures HYTN exclusive rights to Prism’s intellectual property and technologies that promise to boost mushroom yield and potency. This strategic move aligns with HYTN’s aspiration to be a leader in supplying psychoactive compounds for clinical use in federally regulated markets.
For further insights into TSE:HYTN stock, check out TipRanks’ Stock Analysis page.
